Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination RatesA Cluster Randomized Clinical Trial

Posted on by

JAMA Pediatrics
September 2021, Vol 175, No. 9, Pages 886-984
https://jamanetwork.com/journals/jamapediatrics/currentissue

 

Original Investigation
Effect of Training Pediatric Clinicians in Human Papillomavirus Communication Strategies on Human Papillomavirus Vaccination RatesA Cluster Randomized Clinical Trial
Peter G. Szilagyi, MD, MPH; Sharon G. Humiston, MD, MPH; Alisa J. Stephens-Shields, PhD; et al.
JAMA Pediatr. 2021;175(9):901-910. doi:10.1001/jamapediatrics.2021.0766
This cluster randomized clinical trial evaluates the effect of online communication training for clinicians on missed opportunities for HPV vaccination rates overall and at well-child care visits and visits for acute or chronic illness and on adolescent HPV vaccination rates.

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England

Posted on by

JAMA Pediatrics
September 2021, Vol 175, No. 9, Pages 886-984
https://jamanetwork.com/journals/jamapediatrics/currentissue

 

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England
Defne Saatci, MD; Tom A. Ranger, PhD; Cesar Garriga, PhD; et al.
free access has active quiz
JAMA Pediatr. 2021;175(9):928-938. doi:10.1001/jamapediatrics.2021.1685
This cohort study investigates the association between race and childhood COVID-19 testing and hospital outcomes in children from family practices in England.

Violence and COVID-19 across the Globe

Posted on by

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 32, Number 3, August 2021
https://muse.jhu.edu/issue/45771

 

Table of Contents
Violence and COVID-19 across the Globe
Virginia Brennan, PhD, MAEditor, JHCPU
As the summer of 2021 simmers on, JHCPU again publishes a large collection of papers delving into the complex sea of health inequities. In this Note, to stand in for the large array of topics the issue covers, I highlight a small selection, two papers concerning violence, two on COVID-19, and two concerning sub-Saharan African nations…

Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination

Posted on by

Journal of Infectious Diseases
Volume 224, Issue 6, 15 September 2021
https://academic.oup.com/jid/issue/224/6

 

COVID-2019
Editor’s Choice
Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination
Sarah M Bartsch, Patrick T Wedlock, Kelly J O’Shea, Sarah N Cox, Ulrich Strych …
The Journal of Infectious Diseases, Volume 224, Issue 6, 15 September 2021, Pages 938–948, https://doi.org/10.1093/infdis/jiab233
Our study quantifies the potential value of decreasing vaccine hesitancy, increasing vaccination coverage, and how this may decrease with the time it takes to achieve coverage, emphasizing the need to reach high coverage levels as soon as possible, especially before fall/winter.

Citizen science and biomedical research

Posted on by

The Lancet Child & Adolescent Health
Oct 2021 Volume 5 Number 10 p681-766, e39-e43
https://www.thelancet.com/journals/lanchi/issue/current

 

Comment
Citizen science and biomedical research
Dana Mahr, Bruno J Strasser
…Paediatrics, even more than other medical specialties, has long been confronted with the problem that the patient’s voice is often mediated through that of their parent or caregiver. It is a characteristic of modern hospital medicine that the complex patient illness narrative has been replaced by a professional description of signs and symptoms, framed in medical categories. But nowadays, online participatory health research projects such as the COVID Symptom Study once again offer the possibility for patients to freely describe how they feel, outside of scientific and medical categories and vocabularies. Such illness narratives can now be processed automatically by analysing word frequency, as in the present paper, although more refined methods relying on artificial intelligence might better preserve the singularity of the individual patient’s experience. Finally, as with all participatory initiatives, it is important not just to ask what researchers have gained from such studies, but what was the experience of the people enrolled and whether it matched their expectations. Entering data on a smartphone app is not equivalent to discussing with a paediatrician or health-care worker who can answer further questions and concerns of participants, an especially important factor for underserved communities. In the end, the app has no emotive quality, even if those designing it do. Citizen science will continue to require a close interaction with professional medical researchers to turn unique illness experiences into research data.

Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review

Posted on by

Lancet Digital Health
Sep 2021 Volume 3 Number 9 e534-e611
https://www.thelancet.com/journals/landig/issue/current

 

Review
Patient and general public attitudes towards clinical artificial intelligence: a mixed methods systematic review
Albert T Young, Dominic Amara, Abhishek Bhattacharya, Maria L Wei
Summary
Artificial intelligence (AI) promises to change health care, with some studies showing proof of concept of a provider-level performance in various medical specialties. However, there are many barriers to implementing AI, including patient acceptance and understanding of AI. Patients’ attitudes toward AI are not well understood. We systematically reviewed the literature on patient and general public attitudes toward clinical AI (either hypothetical or realised), including quantitative, qualitative, and mixed methods original research articles. We searched biomedical and computational databases from Jan 1, 2000, to Sept 28, 2020, and screened 2590 articles, 23 of which met our inclusion criteria. Studies were heterogeneous regarding the study population, study design, and the field and type of AI under study. Six (26%) studies assessed currently available or soon-to-be available AI tools, whereas 17 (74%) assessed hypothetical or broadly defined AI. The quality of the methods of these studies was mixed, with a frequent issue of selection bias. Overall, patients and the general public conveyed positive attitudes toward AI but had many reservations and preferred human supervision. We summarise our findings in six themes: AI concept, AI acceptability, AI relationship with humans, AI development and implementation, AI strengths and benefits, and AI weaknesses and risks. We suggest guidance for future studies, with the goal of supporting the safe, equitable, and patient-centred implementation of clinical AI.

Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis

Posted on by

Lancet Global Health
Oct 2021 Volume 9 Number 10 e1336-e1473
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Economic impact of tuberculosis mortality in 120 countries and the cost of not achieving the Sustainable Development Goals tuberculosis targets: a full-income analysis
Sachin Silva, et al.

COVID-19 vaccine equity and booster doses

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Editorial
COVID-19 vaccine equity and booster doses
The Lancet Infectious Diseases
The debate on COVID-19 vaccine equity has been long-running, and we have previously weighed in on the topic. However, the facts that (1) by Aug 9, only 12·6 million of the 4·46 billion doses administered globally were in low-income countries, (2) 3·65 billion have been administered in high-income (HICs) and upper-middle-income countries, and (3) WHO Director-General Tedros Adhanom Ghebreyesus actually had to issue a plea for a moratorium on third-dose boosters in HICs on Aug 4, mean that we, again, need to add our voice to the demand for equitable access to vaccines.

“No one is safe until everyone is safe” has become the mantra of the COVID-19 pandemic, with good reason. Unmitigated transmission means rampant viral replication, which in turn means infinite opportunities for the emergence of new, more transmissible variants that could escape natural or vaccine-induced immunity. A perverse social experiment would be to allow the virus to continue ripping through low-income and lower-middle-income countries (LMICs), where people tend to live in close proximity and infection prevention strategies are difficult to implement because much of the populations rely on hand-to-mouth income (India being a case-in-point), while seeing how quickly HICs can redesign vaccines to counter yet another variant that has emerged from LMICs. Beyond the moral argument, this approach would make no economic sense: if many final goods in HICs rely on raw materials and intermediate goods from LMICs, and if LMICs cannot provide these materials because their populations are dying from COVID-19 or are prevented from working because of lockdowns, how long do HICs think that they can keep their own economies running? The RAND corporation estimates that HICs would see a return of US$4·8 for every $1 spent on supplying vaccines to LMICs, and the Global Dashboard for Vaccine Equity shows that if vaccine distribution were uniform, HICs still stand to gain the most. Additionally, while HICs hoard their precious vaccines, China and Russia, two ambitious political entities, have been only too happy to offer their vaccines and strengthen their spheres of influence in Africa, South America, southeast Asia, the Middle East, and eastern Europe.

The administration of a third dose is motivated by fear of the B.1.617.2 (delta) variant but the intensity of this fear is unfounded, as there is now evidence that vaccines licensed in HICs are effective enough against it. Conversely, there is no definitive evidence if, and when, a third dose is necessary, and much-needed trials—the only context in which third-dose administration should be acceptable—are eagerly awaited. There is some evidence of waning antibody titres, which is an axiom of any vaccine administration that does not equal waning cellular immunity. Although the world has ubiquitously grappled with the plague of vaccine hesitancy, the level of coverage in HICs and the rates of administration of new doses should now be sufficient to allow the redirection of surplus doses to those who have none via the COVAX initiative. It is deeply ironic that COVID-19 vaccine acceptance might actually be much higher in LMICs than in HICs. A point must also be made about increasingly risky behaviour—it is irresponsible to encourage relaxation of basic physical distancing measures such as mask wearing in public or confined spaces even for vaccinated individuals, which may well be contributing to a large proportion of breakthrough infections.

A crucial problem for getting vaccines to LMICs is an interrupted cold chain. This is the case in Africa, where many communities live without continuous power supplies, and freezers that cost up to $20 000 are unaffordable. While capacity building is ongoing, countries could focus on donating and administering vector vaccines that are easier to store than mRNA vaccines and are sufficiently safe and effective, particularly in older individuals. Preliminary evidence from the Com-COV trial shows that heterologous vaccination is safe and induces robust immune responses, a viable option for countries that cannot rely on a steady stream of vaccines. There have been calls, reasonable in a time of global catastrophe, to waive intellectual property rights to facilitate local vaccine manufacturing, which should currently focus on LMICs with sufficiently robust regulatory capacities to ensure the quality of local production, as argued by the Center for Global Development. Vaccine donors and corporations can think about how to help with these issues in the short and long terms.

Vulnerable people in HICs have already been prioritised; vulnerable people in LMICs cannot wait until 2023 for their turn, and this wait is in the best interest of no one.

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Paul A Goepfert, et al.

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
Timo Vesikari,et al. for the PROTECT Study Group

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial
Htay-Htay Han, et al.

Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance

Posted on by

Lancet Infectious Diseases
Sep 2021 Volume 21 Number 9 p1193-1332, e258-e301
https://www.thelancet.com/journals/laninf/issue/current

 

Impact of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease and pneumonia in The Gambia: 10 years of population-based surveillance
The Gambia Pneumococcal Surveillance Group,
Grant A Mackenzie, et al.
Open Access

BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers

Posted on by

Lancet Respiratory Medicine
Aug 2021 Volume 9 Number 8 p803-936, e69-e87
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
Yaniv Lustig, et al

Behavioural nudges increase COVID-19 vaccinations

Posted on by

Nature
Volume 597 Issue 7876, 16 September 2021
https://www.nature.com/nature/volumes/597/issues/7875

 

Article | 02 August 2021 | Open Access
Behavioural nudges increase COVID-19 vaccinations
Two randomized controlled trials demonstrate the ability of text-based behavioural ‘nudges’ to improve the uptake of COVID-19 vaccines, especially when designed to make participants feel ownership over their vaccine dose.
Hengchen Dai, Silvia Saccardo, Daniel M. Croymans

FoGS provides a public FAQ repository for social and behavioral genomic discoveries

Posted on by

Nature Genetics
Volume 53 Issue 9, September 2021
https://www.nature.com/ng/volumes/53/issues/9

 

Comment | 06 September 2021
FoGS provides a public FAQ repository for social and behavioral genomic discoveries
Here we introduce ‘FAQs on Genomic Studies’ (FoGS), an open-access repository of explanatory documents that accompany genomic analyses in social and behavioral genomics. For fields such as social and behavioral genomics that are shaped by an ugly history and uncertain future, socially and ethically responsible research and research communication are crucial. FoGS amplifies one such approach towards responsible research communication.
Daphne Oluwaseun Martschenko, Benjamin W. Domingue, Sam Trejo

Balancing incentives and disincentives for vaccination in a pandemic

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Comment | 06 September 2021
Balancing incentives and disincentives for vaccination in a pandemic
Mandates and incentives are being considered to increase uptake of vaccines against COVID-19, but payment for vaccination may be the fairest approach.
Julian Savulescu, Jonathan Pugh, Dominic Wilkinson

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Article | 09 July 2021
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively.
Hiam Chemaitelly, Hadi M. Yassine, Laith J. Abu-Raddad

Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial

Posted on by

Nature Medicine
Volume 27 Issue 9, September 2021
https://www.nature.com/nm/volumes/27/issues/9

 

Article | 13 September 2021
Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial
The PfSPZ Vaccine does not protect infants from infection with Plasmodium falciparum, the major cause of malaria.
Martina Oneko, Laura C. Steinhardt, Robert A. Seder

SARS-CoV-2 and HIV-1 — a tale of two vaccines

Posted on by

Nature Reviews Immunology
Volume 21 Issue 9, September 2021
https://www.nature.com/nri/volumes/21/issues/9

 

Comment | 16 July 2021
SARS-CoV-2 and HIV-1 — a tale of two vaccines
It took roughly 1 year for a COVID-19 vaccine to become available, yet, four decades after the first patient with HIV was described, we do not yet have a vaccine for HIV. Here, Barton Haynes examines the biological reasons why vaccine development for HIV is so exceptionally challenging.
Barton F. Haynes

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 18 Sep 2021]

 

Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria
Angela E. Oyo-Ita, Patrick Hanlon, Ogonna Nwankwo, Xavier Bosch-Capblanch, Dachi Arikpo, Ekperonne Esu, Christian Auer, Martin Meremikwu
Research Article | published 16 Sep 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0257277

Incentives can spur COVID-19 vaccination uptake

Posted on by

PNAS – Proceedings of the National Academy of Sciences of the United States
September 07, 2021; vol. 118 no. 36
https://www.pnas.org/content/118/36

 

Brief Reports
Incentives can spur COVID-19 vaccination uptake
Heike Klüver, Felix Hartmann, Macartan Humphreys, Ferdinand Geissler, and Johannes Giesecke
PNAS September 7, 2021 118 (36) e2109543118; https://doi.org/10.1073/pnas.2109543118

The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts

Posted on by

Preventive Medicine
Volume 150 September 2021
https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C

 

Research article Abstract only
The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts
M. Clark, N. Jembere, R. Kupets
Article 106641

Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin

Posted on by

Public Health Reports
Volume 136 Issue 5, September/October 2021
https://journals.sagepub.com/toc/phrg/136/5

 

Research
Applying the AFIX Quality Improvement Model to Increase Adult Immunization in Wisconsin
Stephanie M. Borchardt, PhD, MPH, Kailynn Mitchell, MPH, Taylor Larson, MPH, Ellen Ehlers, MSW, Stephanie L. Schauer, PhD
First Published February 9, 2021; pp. 603–608

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Posted on by

Science
Volume 373| Issue 6561| 17 Sep 2021
https://www.science.org/toc/science/current

 

Reports
Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
BY Amarendra Pegu et al.
13 Aug 2021: 1372-1377
Open Access
Most individuals vaccinated with mRNA-1273 develop functional antibodies against SARS-CoV-2 variants for at least 6 months.

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Posted on by

Science
Volume 373| Issue 6561| 17 Sep 2021
https://www.science.org/toc/science/current

 

Research Articles
Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates
BY Kizzmekia S. Corbett et al.
17 Sep 2021
Open Access
mRNA-1273 vaccine–induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in nonhuman primates.

Process evaluation of complex interventions in chronic and neglected tropical diseases in low- and middle-income countries—a scoping review protocol

Posted on by

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 18 Sep 2021]

 

Process evaluation of complex interventions in chronic and neglected tropical diseases in low- and middle-income countries—a scoping review protocol
The use of process evaluations is a growing area of interest in research groups working on complex interventions. This methodology tries to understand how the intervention was implemented to inform policy and practice. A recent systematic review by Liu et al. on process evaluations of complex interventions addressing non-communicable diseases found few studies in low- and middle- income countries (LMIC) because it was restricted to randomized controlled trials, primary healthcare level and non-communicable diseases. Yet, LMICs face different barriers to implement interventions in comparison to high-income countries such as limited human resources, access to health care and skills of health workers to treat chronic conditions especially at primary health care level. Therefore, understanding the challenges of interventions for non-communicable diseases and neglected tropical diseases (diseases that affect poor populations and have chronic sequelae) will be important to improve how process evaluation is designed, conducted and used in research projects in LMICs. For these reasons, in comparison to the study of Liu et al., the current study will expand the search strategy to include different study designs, languages and settings.
Authors: María Lazo-Porras, Hueiming Liu, J. Jaime Miranda, Graham Moore, Mafalda Burri, François Chappuis, Pablo Perel and David Beran
Content type: Protocol
Published on: 7 September 2021

COVID-19 Vaccine Donations—Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review

Posted on by

Vaccines
https://www.mdpi.com/journal/vaccines

 

Open Access Review
COVID-19 Vaccine Donations—Vaccine Empathy or Vaccine Diplomacy? A Narrative Literature Review
by Zhaohui Su et al.
Vaccines 2021, 9(9), 1024; https://doi.org/10.3390/vaccines9091024 – 15 Sep 2021
Abstract
Introduction: Vaccine inequality inflames the COVID-19 pandemic. Ensuring equitable immunization, vaccine empathy is needed to boost vaccine donations among capable countries. However, damaging narratives built around vaccine donations such as “vaccine diplomacy” could undermine nations’ willingness to donate their vaccines, which, in turn, […

medRxiv

Posted on by

medRxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
https://www.medrxiv.org/content/about-medrxiv
[Accessed 18 Sep 2021]

Selected Content
A Vaccination Simulator for COVID-19: Effective and Sterilizing Immunization Cases.
Aknur Karabay, Askat Kuzdeuov, Shyryn Ospanova, Michael Lewis, Atakan Huseyin Varol
medRxiv 2021.03.28.21254468; doi: https://doi.org/10.1101/2021.03.28.21254468 Revision

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals
Tawanda Chivese, Joshua Matizanadzo, Omran Musa, George Hindy, Luis Furuya-Kanamori, Nazmul Islam, Rafal Al-Shebly, Rana Shalaby, Mohammad Habibullah, Talal Al-Marwani, Rizeq F Hourani, Ahmed D Nawaz, Mohammad Haider, Mohamed M Emara, Farhan Cyprian, Suhail A. R. Doi
medRxiv 2021.09.03.21263103; doi: https://doi.org/10.1101/2021.09.03.21263103

COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021
Brechje de Gier, Marjolein Kooijman, Jeanet Kemmeren, Nicolette de Keizer, Dave Dongelmans, Senna C.J.L. van Iersel, Jan van de Kassteele, Stijn P. Andeweg, the RIVM COVID-19 epidemiology and surveillance team, Hester E. de Melker, Susan J.M. Hahné, Mirjam J. Knol, Susan van den Hof
medRxiv 2021.09.15.21263613; doi: https://doi.org/10.1101/2021.09.15.21263613

Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study
Paul M McKeigue, David A McAllister, Chris Robertson, Sharon Hutchinson, Stuart McGurnaghan, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
medRxiv 2021.09.13.21262360; doi: https://doi.org/10.1101/2021.09.13.21262360

Interrogating COVID-19 Vaccine Hesitancy in the Philippines with a Nationwide Open-Access Online Survey
Alexandria Caple, Arnie O. Dimaano, Marc Martin C. Sagolili, April Anne M. Uy, Panjee Mariel G. Aguirre, Dean Lotus C. Alano, Giselle Sophia M. Camaya, Brent John A. Ciriaco, Princess Jerah S. Clavo, Dominic G. Cuyugan, Cleinne Florence Geeseler V. Fermo, Paul Jeremy C. Lanete, Ardwayne Jurel D. La Torre, Thomas Albert T. Loteyro, Raisa Mikaela Lua, Nicole Gayle R. Manansala, Raphael Willard M. Mosquito, Alexa Marie C. Octaviano, Alexandra Erika T. Orfanel, Gheyanna Merly U. Pascual, Aubrey Joy S. Sale, Sophia Lorraine S. Tendenilla, Maria Sofia Lauren R. Trinidad, Nicole Jan S. Trinidad, Daphne Louise V. Verano, Nicanor Austriaco
medRxiv 2021.09.11.21263428; doi: https://doi.org/10.1101/2021.09.11.21263428

Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study
Paul M McKeigue, David A McAllister, Sharon J Hutchinson, Chris Robertson, Diane Stockton, Helen M Colhoun, for the PHS COVID-19 Epidemiology and Research Cell
medRxiv 2021.09.12.21263448; doi: https://doi.org/10.1101/2021.09.12.21263448

Effectiveness of Mass Vaccination in Brazil against Severe COVID-19 Cases
Daniel A.M. Villela, Tatiana Guimarães de Noronha, Leonardo S. Bastos, Antonio G. Pacheco, Oswaldo G Cruz, Luiz Max Carvalho, Claudia Torres Codeço, Marcelo Ferreira da Costa Gomes, Flávio Codeço Coelho, Laís Picinini Freitas, Raquel Martins Lana, Victor Bertollo Gomes Porto, Luiz Antônio Bastos Camacho, Claudio José Struchiner
medRxiv 2021.09.10.21263084; doi: https://doi.org/10.1101/2021.09.10.21263084

Safety, Immunogenicity, and Efficacy of COVID-19 Vaccine in Children and Adolescents: A Systematic Review
Meng Lv, Xufei Luo, Quan Shen, Ruobing Lei, Xiao Liu, Enmei Liu, Qiu Li, Yaolong Chen
medRxiv 2021.09.11.21262855; doi: https://doi.org/10.1101/2021.09.11.21262855

Predictors of real-world parents’ acceptance to vaccinate their children against the COVID-19
Petros Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiroumpa, Ioannis Moisoglou, Daphne Kaitelidou
medRxiv 2021.09.12.21263456; doi: https://doi.org/10.1101/2021.09.12.21263456

Think Tanks et al

Posted on by

Think Tanks et al
 
 
Brookings [to 18 Sep 2021]
http://www.brookings.edu/
Up Front
The game is not yet over, and vaccines still matter: Lessons from a study on Israel’s COVID-19 vaccination
Oren Heller, Yaniv Shlomo, Yung Chun, Mary Acri, and Michal Grinstein-Weiss
Monday, September 13, 2021
 
 
Center for Global Development [to 18 Sep 2021]
http://www.cgdev.org/page/press-center
Accessed 18 Sep 2021
[No new digest content identified]
 
 
Chatham House [to 18 Sep 2021]
https://www.chathamhouse.org/
Accessed 18 Sep 2021
[No new digest content identified]

 
 
CSIS
https://www.csis.org/
Accessed 18 Sep 2021
Podcast Episode
Dr. LaQuandra S. Nesbitt: “Vaccine Requirements Will Get Us Over The Finish Line”
September 17, 2021 | By J. Stephen Morrison, H. Andrew Schwartz

Blog Post
In Southeast Asia, Privatized Vaccination Schemes Gain Traction
September 16, 2021 | By Simon Tran Hudes

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
September 14, 2021 News Release
Preventable Costs of Unvaccinated COVID-19 Patients Rise Sharply in August as Hospitalizations Surge
A surge in COVID-19 hospitalizations among people who have not been vaccinated in August is adding billions of dollars in preventable costs to the nation’s health-care system, an updated KFF analysis finds. In August, the new analysis estimates that the preventable costs of treating unvaccinated patients in  hospitals total $3.7…
 
 
Rand [to 18 Sep 2021]
https://www.rand.org/pubs.html
Selected Research Reports, Featured Journal Articles
Report
Identifying Strategies to Boost COVID-19 Vaccine Acceptance in the United States
Sep 9, 2021
This report recommends strategies to help boost COVID-19 vaccine acceptance in the United States in order to reach herd immunity and end the pandemic.
Florian F. Schmitzberger, Kirstin W. Scott, Wilson Nham, Kusum Mathews, Lucy Schulson, Sydney Fouche, Nasma Berri, Alex Shehab, Ashwin Gupta, Rama A. Salhi, Neil Kamdar, Jennifer Bouey, Mahshid Abir
 
 
World Economic Forum [to 18 Sep 2021]
https://agenda.weforum.org/news/
Media
India Completes First Drone Delivery of Vaccines, Start of New Pilot Programme with World Economic Forum
News 18 Sep 2021

Majority Want to Prioritize Equitable Access to COVID-19 Vaccines Before Boosters
News 10 Sep 2021
Health experts say at least 60% of world’s population needs to be vaccinated by 2022 to get the current pandemic under control – but only 0.4% of doses have been administered in low-income countries
Majority would receive a booster shot, but think priority goes to people yet to have a full dose
Read the full report

Vaccines and Global Health: The Week in Review :: 11 September 2021

Posted on by

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

– pdf version:  A pdf of the current issue is available here: 

vaccines-and-global-health_the-week-in-review_11-sep-2021Download

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

COVID

Posted on by

Milestones :: Perspectives :: Research

 

COVID

 

Editor’s Note:
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive, If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me…we will review all suggestions and consider for inclusion in a subsequent edition: david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.